FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1635278082> ?p ?o ?g. }

• W1635278082 endingPage "651" @default.
• W1635278082 startingPage "651" @default.
• W1635278082 abstract "Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia Damon A Bell,1–3 Amanda J Hooper,1,2,4 Gerald F Watts,2,3 John R Burnett1–41Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine, 2School of Medicine and Pharmacology, 3Lipid Disorders Clinic, Department of Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia; 4School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, AustraliaAbstract: Familial hypercholesterolemia (FH) is an autosomal dominant condition with a population prevalence of one in 300–500 (heterozygous) that is characterized by high levels of low-density lipoprotein (LDL) cholesterol, tendon xanthomata, and premature atherosclerosis and coronary heart disease (CHD). FH is caused mainly by mutations in the LDLR gene. However, mutations in other genes including APOB and PCSK9, can give rise to a similar phenotype. Homozygous FH with an estimated prevalence of one in a million is associated with severe hypercholesterolemia with accelerated atherosclerotic CHD in childhood and without treatment, death usually occurs before the age of 30 years. Current approaches for the treatment of homozygous FH include statin-based lipid-lowering therapies and LDL apheresis. Mipomersen is a second-generation antisense oligonucleotide (ASO) targeted to human apolipoprotein B (apoB)-100. This review provides an overview of the pathophysiology and current treatment options for familial hypercholesterolemia and describes novel therapeutic strategies focusing on mipomersen, an antisense apoB synthesis inhibitor. Mipomersen is distributed mainly to the liver where it silences apoB mRNA, thereby reducing hepatic apoB-100 and giving rise to reductions in plasma total cholesterol, LDL-cholesterol, and apoB concentrations in a dose- and time-dependent manner. Mipomersen has been shown to decrease apoB, LDL-cholesterol and lipoprotein(a) in patients with heterozygous and homozygous FH on maximally tolerated lipid-lowering therapy. The short-term efficacy and safety of mipomersen has been established, however, injection site reactions are common and concern exists regarding the long-term potential for hepatic steatosis with this ASO. In summary, mipomersen given alone or in combination with standard lipid-lowering medications shows promise as an adjunct therapy in patients with homozygous or refractory heterozygous FH at high risk of atherosclerotic CHD, who are not at target or are intolerant of statins.Keywords: antisense oligonucleotide, apolipoprotein B, familial hypercholesterolemia, LDL-cholesterol, metabolism, mipomersen" @default.
• W1635278082 created "2016-06-24" @default.
• W1635278082 creator A5006036283 @default.
• W1635278082 creator A5009026091 @default.
• W1635278082 creator A5066973981 @default.
• W1635278082 creator A5079564889 @default.
• W1635278082 date "2012-11-01" @default.
• W1635278082 modified "2023-10-14" @default.
• W1635278082 title "Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia" @default.
• W1635278082 cites W1538707925 @default.
• W1635278082 cites W1549090036 @default.
• W1635278082 cites W1923289550 @default.
• W1635278082 cites W1968949098 @default.
• W1635278082 cites W1975036384 @default.
• W1635278082 cites W1976358128 @default.
• W1635278082 cites W1980017699 @default.
• W1635278082 cites W1981005567 @default.
• W1635278082 cites W1987451368 @default.
• W1635278082 cites W1989730880 @default.
• W1635278082 cites W1994621034 @default.
• W1635278082 cites W2004410658 @default.
• W1635278082 cites W2009186716 @default.
• W1635278082 cites W2014333297 @default.
• W1635278082 cites W2023572044 @default.
• W1635278082 cites W2025664844 @default.
• W1635278082 cites W2025787794 @default.
• W1635278082 cites W2026205222 @default.
• W1635278082 cites W2026934511 @default.
• W1635278082 cites W2028976140 @default.
• W1635278082 cites W2033080889 @default.
• W1635278082 cites W2034152285 @default.
• W1635278082 cites W2034425055 @default.
• W1635278082 cites W2038169981 @default.
• W1635278082 cites W2040612932 @default.
• W1635278082 cites W2043748634 @default.
• W1635278082 cites W2048760408 @default.
• W1635278082 cites W2049718801 @default.
• W1635278082 cites W2054119723 @default.
• W1635278082 cites W2056411372 @default.
• W1635278082 cites W2058129495 @default.
• W1635278082 cites W2059426381 @default.
• W1635278082 cites W2066400199 @default.
• W1635278082 cites W2067539811 @default.
• W1635278082 cites W2068102823 @default.
• W1635278082 cites W2069271102 @default.
• W1635278082 cites W2084744450 @default.
• W1635278082 cites W2087714109 @default.
• W1635278082 cites W2090464684 @default.
• W1635278082 cites W2090883245 @default.
• W1635278082 cites W2091534448 @default.
• W1635278082 cites W2096075279 @default.
• W1635278082 cites W2098230963 @default.
• W1635278082 cites W2102953109 @default.
• W1635278082 cites W2104355263 @default.
• W1635278082 cites W2110994303 @default.
• W1635278082 cites W2114918865 @default.
• W1635278082 cites W2115913745 @default.
• W1635278082 cites W2120289695 @default.
• W1635278082 cites W2127445212 @default.
• W1635278082 cites W2127791131 @default.
• W1635278082 cites W2128030263 @default.
• W1635278082 cites W2130869061 @default.
• W1635278082 cites W2142526970 @default.
• W1635278082 cites W2143001636 @default.
• W1635278082 cites W2143741651 @default.
• W1635278082 cites W2145073911 @default.
• W1635278082 cites W2148041292 @default.
• W1635278082 cites W2148609678 @default.
• W1635278082 cites W2151675684 @default.
• W1635278082 cites W2156299572 @default.
• W1635278082 cites W2157668743 @default.
• W1635278082 cites W2158624779 @default.
• W1635278082 cites W2162679776 @default.
• W1635278082 cites W2163488353 @default.
• W1635278082 cites W2168470530 @default.
• W1635278082 cites W2325179266 @default.
• W1635278082 cites W1482285479 @default.
• W1635278082 doi "https://doi.org/10.2147/vhrm.s28581" @default.
• W1635278082 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3513909" @default.
• W1635278082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23226021" @default.
• W1635278082 hasPublicationYear "2012" @default.
• W1635278082 type Work @default.
• W1635278082 sameAs 1635278082 @default.
• W1635278082 citedByCount "34" @default.
• W1635278082 countsByYear W16352780822013 @default.
• W1635278082 countsByYear W16352780822014 @default.
• W1635278082 countsByYear W16352780822015 @default.
• W1635278082 countsByYear W16352780822016 @default.
• W1635278082 countsByYear W16352780822018 @default.
• W1635278082 countsByYear W16352780822019 @default.
• W1635278082 countsByYear W16352780822021 @default.
• W1635278082 countsByYear W16352780822022 @default.
• W1635278082 countsByYear W16352780822023 @default.
• W1635278082 crossrefType "journal-article" @default.
• W1635278082 hasAuthorship W1635278082A5006036283 @default.
• W1635278082 hasAuthorship W1635278082A5009026091 @default.
• W1635278082 hasAuthorship W1635278082A5066973981 @default.
• W1635278082 hasAuthorship W1635278082A5079564889 @default.

• next